BPC-157 or TB-500? How Two Repair Peptides Differ in Mechanism, Models and Use
Researchers studying repair biology reach for BPC-157 and TB-500 more than for any other peptides, and the two are frequently treated as substitutes. They aren’t. Treating them as one obscures how differently they work, and why studies compare or combine them in the first place.
The short version
TB-500 works on whether cells can move. BPC-157’s reported effects concern the environment those cells move into. That split, cell motility on one side and the local tissue setting on the other, explains most of the differences on this page.
Matching the peptide to the question
- Cell movement. Scratch assays, chemotaxis and other migration questions belong with TB-500 and its actin mechanism.
- Vessels, gut lining and tendon cells. Vascularization, GI cytoprotection and tendon fibroblast models belong with BPC-157.
- Head-to-head or combined arms. Designs that compare the two, or test them together, need both.
Why combination designs exist
Each compound acts on a different layer of the repair cascade, and that is the reason combinations appear in the literature and in lab practice. A cell can only enter a wound bed by migrating, and migration is actin-dependent by definition, so TB-500 bears on whether cells arrive. What BPC-157 is reported to affect is the tissue they arrive in: vascularization, growth-factor expression and cytoprotection. At the bench the difference becomes a choice of assay, with migration and scratch tests for TB-500 and angiogenesis and survival assays for BPC-157.
Both compounds at Welon Peptide
We list BPC-157 (5mg, 10mg), TB-500 (Thymosin Beta-4) (2mg, 5mg, 10mg) and the BPC-157 + TB-500 Blend (10mg, 20mg, 30mg). Single-compound vials let you run each agent on its own alongside a combined arm.
The lab record differs across the three. Our COAs page lists 5 passed Finnrick tests of Welon Peptide Solutions BPC-157 (18 Feb to 5 May 2026, purity 99.78% to 99.9%) and 2 of its TB-500 (Thymosin Beta-4) (5 May and 9 Aug 2026, purity 99.9% and 99.6%). It lists no test of the blend itself. These are the passed tests shown on our page; Finnrick publishes the full history for each product, and each result covers only the sample tested.
Reference table
| TB-500 (Tβ4) | BPC-157 | |
|---|---|---|
| Human trials published | Ophthalmic only (Tβ4 eye drops) | None |
| Stability | Needs standard peptide handling | Unusually robust; stable in acid |
| Typical models | Skin wounds, corneal repair and cardiac injury in rodents, plus some human eye-drop trials | Tendon and ligament transection and GI mucosal injury, in rodents |
| Main mechanism | Sequesters G-actin, which drives cell migration and differentiation | Cytoprotection, VEGF-linked angiogenesis, NO-system modulation, and fibroblast migration through FAK–paxillin |
| Length and mass | 43 amino acids (~4.9 kDa), or an active fragment | 15 amino acids (~1.4 kDa) |
| Origin | Synthetic copy of thymosin beta-4, which the human body makes | Synthetic fragment based on a protein found in human gastric juice |
Full summaries: the BPC-157 overview and the thymosin beta-4 overview. For research use only. Not for human or veterinary use.
